Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas

Melanoma Research

Volumn 19, Issue 3, 2009, Pages 135-141

  Soares De Sá, Bianca Costa ^a,d   Fugimori, Melissa Lissae ^c   Braga Ribeiro, Karina De Cássia ^b   Duprat Neto, João Pedreira ^a   Neves, Rogério Izar ^a   Landman, Gilles ^b  

^a Departments of Skin Oncology   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c Fundação Antônio Prudente

^d Hospital AC Camargo Hospital ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; P21 ACTIVATED KINASE; PEROXIDASE; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; STREPTAVIDIN; CELL CYCLE PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TECHNIQUE; TISSUE MICROARRAY; TISSUE SECTION; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETINOBLASTOMA PROTEIN; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67849124276     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831993f3     Document Type: Article

References (30)

1. Mackie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360:587-591.
2. Gerbaud L, Lejeune ML, Abou-Samra T, Doz M, Mathey MF, D'Incan M, et al. Sentinel network of pathologists; sentinel network of dermatologists for melanoma: epidemiological survey of melanoma in the Auvergne region (France): is there an increased incidence in Auvergne? Eur J Epidemiol 2003; 18:331-335.
3. Katalinic A, Kunze U, Schafer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003; 149:1200-1206.
4. De Vries E, Schouten LJ, Visser O, Eggermont AMM, Coebergh JWW, The Working Group of Regional Cancer Registries. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003; 39:1439-1446.
5. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687-701.
6. Czajkowski R, Drewa T, Wozniak A, Krzyzynska-Malinowska E. Cell cycle in sporadic melanoma. Int J Dermatol 2002; 41:550-556.
7. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-5483.
8. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, et al. Involvement of the pRb/p16/Cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 1996; 73:909-916.
9. Hussein MR, Haemel AK, Wood GS. p53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev 2003; 12:93-100.
10. Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 2004; 94:166-176.
11. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
12. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147.
13. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
14. Pacifico MD, Grover R, Richman P, Daley F, Wilson GD. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 2004; 14:39-42.
15. Elder DE. Pathology of melanoma. Clin Cancer Res 2006; 12:2308-2311.
16. Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD. Identification of P-cadherin in primary melanoma using a tissue microarrayer: prognostic implications in a patient cohort with long-term follow up. Ann Plast Surg 2005; 55:316-320. (Pubitemid 41216093)
17. Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD. nm23 as a prognostic marker in primary cutaneous melanoma: evaluation using tissue microarray in a patient group with long-term follow-up. Melanoma Res 2005; 15 :435-440.
18. Ministry of Health. Cancer National Institute. Estimative/2008: Brazil cancer incidence. Rio de Janeiro: INCA; 2007.
19. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55:2713-2718.
20. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuña MJ, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles a tissue microarray-based study. Am J Pathol 2004; 164:193-203.
21. Zhang H, Rosdahl I. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells. Int J Oncol 2004; 24 :331-335.
22. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003; 95: 723-732.
23. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A (p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42:705-722.
24. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000; 6:3614-3620.
25. Zhang H, Rosdahl I. Expression profiles of Id1 and p16 proteins in all-trans-retinoic acid-induced apoptosis and cell cycle re-distribution in melanoma. Cancer Lett 2005; 217:33-41.
26. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-5447.
27. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. Rewiring ERK-JNK signaling pathways in melanoma. Cancer cell 2007; 11 :447-460.
28. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95:1878-1890.
29. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 2007; 34:247-256.
30. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Florenes VA. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol 1996; 149:1813-1822.